Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
about
The balance of powers: Redox regulation of fibrogenic pathways in kidney injuryPerspectives on systems biology applications in diabetic kidney diseaseMetabolomics and diabetes: analytical and computational approachesUremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic studyPodocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in miceAnalytical approaches to metabolomics and applications to systems biologyUnderstanding kidney disease: toward the integration of regulatory networks across species.Diabetic nephropathy - complications and treatment.Global metabolomic and isobaric tagging capillary liquid chromatography-tandem mass spectrometry approaches for uncovering pathway dysfunction in diabetic mouse aorta.Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification.Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometryDoes combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?GLUT1 enhances mTOR activity independently of TSC2 and AMPK.Urine glycoprotein profile reveals novel markers for chronic kidney diseaseEffects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouseThe Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.Antidiabetic effects of Corni Fructus extract in streptozotocin-induced diabetic ratsIdentification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.Metabolomics in diabetic complications.Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy.Complexity of diabetic nephropathy pathogenesis and design of investigations.Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.Insulin signaling to the glomerular podocyte is critical for normal kidney function.Murine glomerular transcriptome links endothelial cell-specific molecule-1 deficiency with susceptibility to diabetic nephropathy.Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis.Metabolic signature of CKD: the search continues.Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.Sphingosine kinase 1 mediates AGEs-induced fibronectin upregulation in diabetic nephropathy.Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus.Glucose Transporters in Diabetic Kidney Disease-Friends or Foes?Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.Metabolomics and Its Role in the Study of Mammalian Systems
P2860
Q26786137-2921FA82-CC7B-4B08-995C-ABFB86D0579EQ26823206-E63649E3-5F78-49BF-9DAD-0D3083B16A5DQ28084835-84D41D1B-878C-464B-B5F7-71E0516578B5Q33810793-BA48DD18-4A22-4347-BA1F-70DC7FE2AB86Q33995140-C379E4C4-CACE-48F7-A32A-AF591949C455Q34340503-80493534-B990-47FE-9EDC-4624147786A5Q34340510-0BC6A311-CAA2-4BB4-A339-58426F398E49Q34387952-9496B5B8-D2F9-4074-8EDF-EAAB7F379C6FQ34669606-D0EB1CF1-71F1-4FAE-BD02-5D70FFDCC69CQ34998284-E119C432-4EA1-4817-9EE6-518BA87B002FQ35173711-D2CA1969-498B-4613-B555-7FEA34AB4C7CQ35183612-E3FBEC15-1F7A-4789-8C90-47F83B0052F3Q35216825-F044A3CC-8209-4C5A-8A05-BC74093880C4Q35380506-AEF1413E-5705-4126-828F-DEACC09AF62AQ35498269-27302123-A0D4-4285-B24B-909C0770244DQ35973863-872A7E0E-3B31-4C0A-AAB2-BB486357728BQ36053411-05B141B7-2152-4A8F-AA28-8C3042454ECBQ36477207-8277E1DF-6A8B-4692-B043-39B10800444FQ37041169-D87C1BD3-6FBD-433E-8840-07D99033D466Q37066937-C53E942A-A283-4120-8088-34DDE21F6287Q37174513-86DB6DC0-6D38-4905-93E9-62A69C4B657FQ37360464-8C4F1189-1F82-4233-90EE-1982F41DBD8EQ37395321-3A1F0CA2-21F6-47E8-A9C3-D821CFB54CB3Q37510124-31877D83-EFDE-46D0-BCDB-2CBD5BB69122Q38262136-11269ECB-0FE0-4A63-85C1-BD679E1EA05EQ38921141-6C958F6B-7070-4927-BCCD-BDC5628932E3Q41979223-A14DBB3C-2232-4C7D-8056-3B6CA8EE2A40Q42110064-31B95ADD-FB21-4019-BD15-5E03EB2F5F8EQ42253708-E7A1A63B-FA27-48F1-B18F-C4616A647C75Q42707950-A0B86E40-D5F9-48E2-9294-9349761A6C1FQ43195850-24E40DB4-0F46-4736-8170-360734AD8AD4Q43202587-82FE715D-CB23-4F38-9F5A-93614EE8DABAQ43907810-D5473064-3E3A-4153-B545-59AC5848ACDBQ46142286-3DE8C062-10B1-4B1A-AA13-528A303E4281Q52568352-B2889766-EFB0-4537-8B6D-C14B1941014EQ53489601-D6A89AE8-E307-45C2-9E09-16342A9D3BC4Q57797380-332DDF78-59E1-41F4-BD8F-ACBBB621BCBC
P2860
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Rosiglitazone reduces renal an ...... ation of diabetic nephropathy.
@en
type
label
Rosiglitazone reduces renal an ...... ation of diabetic nephropathy.
@en
prefLabel
Rosiglitazone reduces renal an ...... ation of diabetic nephropathy.
@en
P2093
P2860
P1476
Rosiglitazone reduces renal an ...... ration of diabetic nephropathy
@en
P2093
Frank C Brosius
Hongyu Zhang
Jaeman Byun
Jharna Saha
MaryLee Schin
Matthew Lorenz
Matthias Kretzler
Subramaniam Pennathur
P2860
P304
P356
10.1152/AJPRENAL.90208.2008
P577
2008-07-30T00:00:00Z